For millions worldwide, alopecia areata (AA) is far more than hair loss—it is an unpredictable autoimmune condition linked to high rates of anxiety, depression and social isolation. For decades, treatment decisions relied solely on the size of bald patches, often missing the full picture of a patient’s struggle. Now, a landmark update is set to change that.
The 2026 Chinese Guidelines for the Diagnosis and Treatment of Alopecia Areata deliver a paradigm shift in disease management. While the traditional severity of alopecia tool (SALT) score remains a baseline, physicians will now upgrade severity levels based on seven key criteria: complete eyebrow/eyelash loss, poor response to prior therapies, diffuse disease activity, and critically, the patient’s own report of significant psychosocial impairment.
The guidelines provide a clear evidence-based therapeutic ladder. Topical corticosteroids remain first-line for mild cases and children under 12. For patients aged ≥12 years with severe chronic AA (disease duration > 6 months) or rapidly progressive disease, JAK inhibitors (baricitinib, ritlecitinib, ivarmacitinib) are now recommended as first-line systemic therapy. Biologics like dupilumab are highlighted for patients with co-existing atopic disease. The guidelines also mandate routine screening for autoimmune comorbidities and emphasize long-term follow-up to prevent relapse.
The work titled “Chinese Guidelines for the Diagnosis and Treatment of Alopecia Areata (2026 Edition)” was published on Skin (published on May 19, 2026).
Experimental study
Not applicable
Chinese Guidelines for the Diagnosis and Treatment of Alopecia Areata (2026 Edition)
19-May-2026